A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
- Conditions
- AML, Adult RecurrentMDS
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- PureTech
- Target Recruit Count
- 90
- Registration Number
- NCT05829226
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of California Irvine Medical Center, Orange, California, United States
🇺🇸Baptist Health South Florida-Miami Cancer Institute, Miami, Florida, United States
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Advanced Solid TumorTNBC - Triple-Negative Breast CancerGastric CancerLeukemia Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- SillaJen, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT05768932
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸University of Miami Health System, Coral Gables, Florida, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT05756777
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen Collection
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 15
- Registration Number
- NCT05744739
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Fox Chase, Philadelphia, Pennsylvania, United States
Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT05697510
- Locations
- 🇫🇷
CHU de Nantes, Nantes, France
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT05682170
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)Diffuse Large B-cell Lymphoma (DLBCL)Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)MDS/Myeloproliferative Neoplasm (MPN) Overlap SyndromeRichter's SyndromeT-cell LymphomaChronic Myelomonocytic Leukemia (CMML)
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 86
- Registration Number
- NCT05665530
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Interventions
- Biological: Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- German Cancer Research Center
- Target Recruit Count
- 12
- Registration Number
- NCT05662904
- Locations
- 🇩🇪
University Hospital Dresden, Department of Medicine I, Dresden, Germany
🇩🇪University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 184
- Registration Number
- NCT05628623
VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myeloid, AcuteAML Stage, Adult
- Interventions
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2025-02-19
- Target Recruit Count
- 66
- Registration Number
- NCT05603884
- Locations
- 🇨🇳
Bing Xu, Xiamen, Fujian, China